Researchers at the newly formed Institute for Immunology and Informatics at the University of Rhode Island will focus on developing vaccines for diseases that are rampant in poor countries, including malaria, dengue fever, AIDS and tuberculosis, using a "genome-to-vaccine" approach. The institute will have access to the bioinformatics tools of biotech firm EpiVax in exchange for partial rights to potential disease-prevention discoveries.

Related Summaries